Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01121757 · ClinicalTrials.gov registry record · Phase 2
Epigenetic Modulation in Relapsed/Refractory Follicular Lymphoma and Marginal Zone Lymphoma
A Phase 2 study, sponsored by Duke University.
- Terminated
- Registry status
- Phase 2
- Development phase
- 11
- Enrollment target
NCT01121757 is a Phase 2 study that was terminated before completion, run by Duke University. The registered enrollment target is 11 participants.
The verdict
NCT01121757, a Phase 2 study, was terminated before completion, sponsored by Duke University.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 11 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the response and safety in subjects receiving the drugs lenalidomide and azacitidine when each drug is given by itself and when the drugs are taken together. This study is open for patients with relapsed or refractory follicular or marginal zone lymphoma.
Interventions
- DRUG azacitidine
- DRUG lenalidomide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2010-04 |
| Est. Completion | 2016-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01121757
The ClinicalTrials.gov registry entry for NCT01121757 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 11 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Duke University, which has 1,725 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which azacitidine is the first listed.
NCT01121757 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01121757 about?
NCT01121757 is a clinical study titled "Epigenetic Modulation in Relapsed/Refractory Follicular Lymphoma and Marginal Zone Lymphoma". The purpose of this study is to evaluate the response and safety in subjects receiving the drugs lenalidomide and azacitidine when each drug is given by itself and when the drugs are taken together. This study is open for patients with relapsed or refractory follicular or marginal zone lymphoma.
What is the current status of trial NCT01121757?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 11 participants. The study started on 2010-04. Estimated completion is 2016-01.
What interventions are being tested in trial NCT01121757?
The interventions under investigation include: azacitidine (DRUG), lenalidomide (DRUG).
Who is sponsoring clinical trial NCT01121757?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.